Cognetivity Neurosciences (XCNQ:CGN) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cognetivity Neurosciences is: No Data: Cannot be evaluated.

Competitive Comparison of Cognetivity Neurosciences's Risk Assessment

For the Health Information Services subindustry, Cognetivity Neurosciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognetivity Neurosciences's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Risk Assessment falls into.

Cognetivity Neurosciences (XCNQ:CGN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cognetivity Neurosciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognetivity Neurosciences (XCNQ:CGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (XCNQ:CGN) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

CGNSF:USA 1UB:Germany

Address

800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6

Website

https://www.cognetivity.com

Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Executives

Ravinder Kang

Director

Cognetivity Neurosciences (XCNQ:CGN) Headlines

No Headlines